Milena Pavlova, MD, neurologist, and medical director of the sleep testing center at Brigham and Women’s Faulkner hospital, talks about how factors such as the sedative effects of anti-epileptic medications can mask sleep issues and diagnoses in people with epilepsy.
Milena Pavlova, MD, neurologist, and medical director of the sleep testing center at Brigham and Women’s Faulkner hospital, talks about how such factors as too little time in an appointment to screen for sleep as one of many possible reasons sleep disorders are underdiagnosed in people with epilepsy.
This interview took place at the American Academy of Neurology 75th annual meeting in Boston, MA.
Transcript
Are sleep disorders underdiagnosed in people with epilepsy? If so, why?
Yes, is the short answer. Why is always a complex question, no matter what you're talking about. I feel that sleep has traditionally been undervalued by physicians, for one obvious reason. We go through a very strenuous process of residency during which we are implicitly told the sleep doesn't matter, because we don't get to sleep much.
That kind of joke aside, a patient with epilepsy has a chronic disease that requires a lot of complex treatment. There is the treatment with medications, there is the consequence of seizures, there is the consequence of having a chronic disease that affects your consciousness, and all the implications of this. So, it is a complex treatment altogether. Somehow sleep, it's just one component of many different things than the physician has to do. So, that's one reason; they simply might not have enough time to ask about the sleep of the patients.
The second thing is that some of the signs of sleep disorders can be attributed to something else. Because when a patient with frequent seizures has a seizure, often they would be afterward sleepy or confused. So, whatever sleepiness the patient reports can often be attributed to just uncontrolled seizures, appropriately so, but there might be a contributing factor of a sleep disorder. Another thing is that most of the anti-epileptic medications have more or less of a sedating effect. So, a lot of the times the symptoms of sleepiness is attributed to the sedating effect.
Having a chronic disease altogether can make you a little bit more anxious; a little bit more difficult to sleep at night. The whole process of having seizures during the daytime, potentially disrupting the regularity of sleep and wakefulness, can be another reason for poor sleep. So, a lot of the times the sleep complaint gets attributed to something else; that is very common in patients with epilepsy.
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
2 Commerce Drive
Cranbury, NJ 08512